PART I Overview We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (FDA) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites. Demodex blepharitis (blephar is a reference to eyelid an...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-23 | 2025-12-31 | 0001819790-26-000019 | EDGAR | 107K words |
| 2025-02-25 | 2024-12-31 | 0001819790-25-000011 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001819790-24-000018 | EDGAR | — |
| 2023-03-17 | 2022-12-31 | 0001819790-23-000007 | EDGAR | — |
| 2022-03-14 | 2021-12-31 | 0001819790-22-000010 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001819790-21-000010 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001819790-25-000121 | EDGAR | 75K words |
| 2025-08-06 | 2025-06-30 | 0001819790-25-000108 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001819790-25-000078 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001819790-24-000129 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001819790-24-000111 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001819790-24-000063 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001819790-23-000080 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001819790-23-000071 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001819790-23-000030 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001819790-22-000042 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001819790-22-000030 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001819790-22-000023 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-23 | 0001819790-26-000017 | EDGAR | 4K words |
| 2026-02-18 | 0001819790-26-000005 | EDGAR | — |
| 2026-01-12 | 0001819790-26-000002 | EDGAR | — |
| 2025-11-04 | 0001819790-25-000120 | EDGAR | — |
| 2025-08-06 | 0001819790-25-000107 | EDGAR | — |
| 2025-06-18 | 0001819790-25-000100 | EDGAR | — |
| 2025-05-01 | 0001819790-25-000077 | EDGAR | — |
| 2025-03-18 | 0001819790-25-000035 | EDGAR | — |
| 2025-03-13 | 0001193125-25-053978 | EDGAR | — |
| 2025-02-25 | 0001819790-25-000007 | EDGAR | — |
101 total filings indexed. 73 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001819790 |
| Ticker | TARS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.tarsusrx.com |
| Listed | 2020-10-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report